DexCom (DXCM) vs Edwards Lifesciences (EW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
DexCom (DXCM) has outperformed Edwards Lifesciences (EW) over the past year, gaining 27.7% versus a gain of 12.0%. Over five years, EW leads with a -23.4% price change compared with -38.1% for DXCM. Edwards Lifesciences is the larger company by market cap ($49.44 billion vs $31.81 billion), about 1.6 times the size, while DexCom is growing revenue faster (+15.6% vs +11.5%).
On valuation, Edwards Lifesciences trades at a lower forward P/E (25.4x vs 27.0x for DexCom). DexCom converts more of its revenue into profit, with a net margin of 17.9% versus 17.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DXCM | EW |
|---|---|---|
| Share price | $84.30 | $85.78 |
| Market cap | $31.81B | $49.44B |
| 1-day change | +1.09% | -0.81% |
| YTD return | +27.02% | +0.77% |
| 1-year return | +27.67% | +11.98% |
| 5-year return | -38.07% | -23.40% |
| P/E ratio (TTM) | 33.45 | 51.06 |
| Forward P/E | 26.96 | 25.40 |
| EPS (TTM) | $2.52 | $1.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.66B | $6.07B |
| Revenue growth (YoY) | +15.60% | +11.55% |
| Net income (latest FY) | $836.30M | $1.07B |
| Gross margin | 60.10% | 78.01% |
| Operating margin | 19.56% | 20.84% |
| Net margin | 17.94% | 17.69% |
| 52-week high | $92.59 | $96.29 |
| 52-week low | $54.11 | $72.30 |
| Distance from 52-week high | -8.95% | -10.91% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +14.15% | +18.86% |
| Average volume | 4.48M | 3.82M |
| Shares outstanding | 377.36M | 576.40M |
| Employees | 11,000 | 16,000 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Industrial Specialties |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DXCM has outperformed EW by 15.7 percentage points over the past year.
- Edwards Lifesciences trades at a higher earnings multiple (51.1x vs 33.5x trailing P/E).
About DexCom
DXCM stock →DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.
Health Care · Medical/Dental Instruments · 11,000 employees
About Edwards Lifesciences
EW stock →Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.
Health Care · Industrial Specialties · 16,000 employees
DXCM vs EW FAQ
Which is bigger, DexCom or Edwards Lifesciences?
Edwards Lifesciences (EW) is larger, with a market capitalization of $49.44B compared with $31.81B for DexCom (DXCM).
Which stock has performed better over the past year, DXCM or EW?
DXCM returned +27.67% over the past 12 months, compared with +11.98% for EW (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, DXCM or EW?
DXCM has the lower trailing P/E at 33.5, versus 51.1 for EW. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are DexCom and Edwards Lifesciences in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for DexCom and Industrial Specialties for Edwards Lifesciences.